These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 29979295)

  • 21. Review of Clinical Profile of IDegAsp.
    Unnikrishnan AG; Singh AK; Modi KD; Saboo B; Garcha SC; Rao PV
    J Assoc Physicians India; 2015 May; 63(5 Suppl):15-20. PubMed ID: 26548030
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differentiating Basal Insulin Preparations: Understanding How They Work Explains Why They Are Different.
    Cheng AYY; Patel DK; Reid TS; Wyne K
    Adv Ther; 2019 May; 36(5):1018-1030. PubMed ID: 30929185
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of insulin degludec and insulin glargine U300 on glycaemic stability in individuals with type 1 diabetes: A multicentre, randomized controlled crossover study.
    Miura H; Sakaguchi K; Otowa-Suematsu N; Yamada T; So A; Komada H; Okada Y; Hirota Y; Tamori Y; Ogawa W
    Diabetes Obes Metab; 2020 Dec; 22(12):2356-2363. PubMed ID: 32744395
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-Effectiveness of Insulin Degludec Versus Insulin Glargine U300 in the Netherlands: Evidence From a Randomised Controlled Trial.
    Evans M; Moes RGJ; Pedersen KS; Gundgaard J; Pieber TR
    Adv Ther; 2020 May; 37(5):2413-2426. PubMed ID: 32306247
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of pharmacodynamics and pharmacokinetics of insulin degludec and insulin glargine 300 U/mL in healthy cats.
    Gilor C; Culp W; Ghandi S; do Carmo Emidio E Silva JA; Ladhar A; Hulsebosch SE
    Domest Anim Endocrinol; 2019 Oct; 69():19-29. PubMed ID: 31280022
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Switching insulin degludec to insulin glulisine improved nocturnal hypoglycemia and ventricular arrythmia in an elderly type 1 diabetes patient with chronic heart failure: A case report].
    Hajika Y; Kawaguchi Y; Tanaka T; Hamazaki K; Kumeda Y
    Nihon Ronen Igakkai Zasshi; 2022; 59(2):237-243. PubMed ID: 35650058
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of the Efficacy and Safety of Insulin Detemir and Insulin Glargine in Hospitalized Patients with Type 2 Diabetes: A Randomized Crossover Trial.
    Zhang T; Lin M; Li W; Fan X; Du T; Zhao Y; Zhang X
    Adv Ther; 2016 Feb; 33(2):178-85. PubMed ID: 26809253
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Understanding how pharmacokinetic and pharmacodynamic differences of basal analog insulins influence clinical practice.
    Goldman J; Kapitza C; Pettus J; Heise T
    Curr Med Res Opin; 2017 Oct; 33(10):1821-1831. PubMed ID: 28537449
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Insulins NPH, glargine, and detemir, and risk of severe hypoglycemia among working-age adults.
    Strandberg AY; Khanfir H; Mäkimattila S; Saukkonen T; Strandberg TE; Hoti F
    Ann Med; 2017 Jun; 49(4):357-364. PubMed ID: 28042719
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rates of hypoglycaemia are lower in patients treated with insulin degludec/liraglutide (IDegLira) than with IDeg or insulin glargine, regardless of the hypoglycaemia definition used.
    Norwood P; Chen R; Jaeckel E; Lingvay I; Jarlov H; Lehmann L; Heller S
    Diabetes Obes Metab; 2017 Nov; 19(11):1562-1569. PubMed ID: 28417535
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative Benefits and Harms of Basal Insulin Analogues for Type 2 Diabetes: A Systematic Review and Network Meta-analysis.
    Madenidou AV; Paschos P; Karagiannis T; Katsoula A; Athanasiadou E; Kitsios K; Bekiari E; Matthews DR; Tsapas A
    Ann Intern Med; 2018 Aug; 169(3):165-174. PubMed ID: 29987326
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and Safety of Insulin Glargine 300 U/mL versus 100 U/mL in Diabetes Mellitus: A Comprehensive Review of the Literature.
    Vargas-Uricoechea H
    J Diabetes Res; 2018; 2018():2052101. PubMed ID: 29619381
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Durability of insulin degludec plus liraglutide versus insulin glargine U100 as initial injectable therapy in type 2 diabetes (DUAL VIII): a multicentre, open-label, phase 3b, randomised controlled trial.
    Aroda VR; González-Galvez G; Grøn R; Halladin N; Haluzík M; Jermendy G; Kok A; Őrsy P; Sabbah M; Sesti G; Silver R
    Lancet Diabetes Endocrinol; 2019 Aug; 7(8):596-605. PubMed ID: 31189519
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Insulin degludec and insulin glargine 300 U/mL: Which of these two insulins causes less hypoglycemia?
    Buscemi S; Randazzo C; Buscemi C
    J Diabetes Investig; 2019 Nov; 10(6):1595-1596. PubMed ID: 31135100
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Switching from twice-daily glargine or detemir to once-daily degludec improves glucose control in type 1 diabetes. An observational study.
    Galasso S; Facchinetti A; Bonora BM; Mariano V; Boscari F; Cipponeri E; Maran A; Avogaro A; Fadini GP; Bruttomesso D
    Nutr Metab Cardiovasc Dis; 2016 Dec; 26(12):1112-1119. PubMed ID: 27618501
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Insulin degludec versus insulin glargine U100 for patients with type 1 or type 2 diabetes in the US: a budget impact analysis with rebate tables.
    Lane WS; Weatherall J; Gundgaard J; Pollock RF
    J Med Econ; 2018 Feb; 21(2):144-151. PubMed ID: 28945173
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The development of new basal insulins: is there any clinical advantage with their use in type 2 diabetes?
    Maiorino MI; Petrizzo M; Capuano A; Giugliano D; Esposito K
    Expert Opin Biol Ther; 2014 Jun; 14(6):799-808. PubMed ID: 24673155
    [TBL] [Abstract][Full Text] [Related]  

  • 38. All-Cause and Cause-Specific Mortality among Users of Basal Insulins NPH, Detemir, and Glargine.
    Strandberg AY; Hoti FJ; Strandberg TE; Christopher S; Haukka J; Korhonen P
    PLoS One; 2016; 11(3):e0151910. PubMed ID: 27031113
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Insulin degludec as an ultralong-acting basal insulin once a day: a systematic review.
    Wang F; Surh J; Kaur M
    Diabetes Metab Syndr Obes; 2012; 5():191-204. PubMed ID: 22826637
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Understanding the safety of the new ultra long acting basal insulin.
    Ramachandran A; Gupta V; Kesavadev J; Kalra S
    J Assoc Physicians India; 2014 Jan; 62(1 Suppl):35-42. PubMed ID: 25330630
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.